Key Drivers
- High margins
- Negative FCF
- Elevated EV/EBIT
AIAI Summary
TG Therapeutics has become a single‑product commercial‑growth story whose valuation is now predicated on sustained BRIUMVI uptake and successful subcutaneous bioequivalence/pivotal readouts rather than pipeline optionality. Monitor sequential quarterly BRIUMVI starts, receivables/inventory trends and sustainable free‑cash‑flow conversion—misses on these metrics or delays/adverse subcu data would likely produce sharp downside given the current EV/EBIT premium.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Negative FCF
- •Elevated EV/EBIT
TGTX shows strong operating profitability and liquidity but faces cash-generation variability, high receivables/inventory and an elevated EV/EBIT multiple that compresses margin of safety.
Price Behavior
Key Price Behavior Insights:
- •Modest upward bias
- •Nearby support
- •High short-term volatility
Over the last month TGTX shows a modest short-term uptrend (close above the ~$29.50 SMA) with about a 2% rise, nearby support around $27–$28 and resistance near $31.5, but sharp swings (drop to $26.94 and jump to $31.51) increase execution risk.
Sharp drop to $26.94 on 2026-03-12 and spike to $31.51 on 2026-03-17 signaling pronounced short-term volatility
Sentiment & News
Key News Insights:
- •Rapid uptake
- •Phase 3 wins
- •Balance‑sheet build
TG Therapeutics is pivoting around rapid BRIUMVI commercial uptake and supportive Phase 3 data while bolstering the balance sheet with non‑dilutive financing and buybacks despite a near‑term EPS miss.
Strong commercial and clinical momentum plus financial flexibility should support the stock's medium‑term outlook despite short‑term earnings pressure
Similar Companies in Healthcare
Other companies in the same sector with AI ratings